Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II

Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon

Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic

Physiomics secures follow-on UK contract for Phase 2 study support

Ascletis reports positive US Phase I data for oral IL-17 inhibitor ASC50

Dimerix completes adult recruitment in ACTION3 Phase 3 DMX-200 trial

RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL

Vanda files FDA Biologics License Application for imsidolimab in generalized pustular psoriasis

Amferia raises EUR3.5m to advance antimicrobial wound-care platform

Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion

Sobi agrees to acquire Arthrosi Therapeutics

Anixa Biosciences reveals final data from Phase one clinical trial of investigational breast cancer vaccine at 2025 San Antonio Breast Cancer Symposium

Amgen's UPLIZNA receives US FDA approval

Innovent Biologics' mazdutide injection meets Phase 1b clinical study primary endpoint

FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma